What are the recommendations for familial gastric (stomach) cancer surveillance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Surveillance for familial stomach cancer should be performed using high-quality upper endoscopy with image enhancement, gastric mucosal cleansing, and insufflation, and should include a systematic biopsy protocol for mucosal staging, as recommended by the most recent guidelines 1.

Key Recommendations

  • Endoscopy is the best test for screening or surveillance in individuals at increased risk for gastric cancer, and should be performed by an experienced endoscopist 1.
  • High-risk groups for gastric cancer include first-generation immigrants from high-incidence regions, individuals with a family history of gastric cancer, and those with certain hereditary gastrointestinal polyposis or hereditary cancer syndromes 1.
  • H. pylori eradication is essential and serves as an adjunct to endoscopic screening and surveillance for primary and secondary prevention of gastric cancer 1.
  • Gastric biopsies should be obtained according to a systematic protocol, such as the updated Sydney System, to enable histologic confirmation and staging 1.
  • Endoscopists should work with their local pathologists to achieve consensus for consistent documentation of histologic risk-stratification parameters when atrophic gastritis with or without metaplasia is diagnosed 1.

Surveillance Intervals

  • The optimal screening intervals for individuals at increased risk for gastric cancer are not well defined, but should be based on the individual's risk factors and preferences 1.
  • For those with hereditary diffuse gastric cancer (HDGC) due to CDH1 mutations, screening should begin at age 18-20 with upper endoscopy every 6-12 months 1.
  • For individuals with other high-risk syndromes, endoscopic surveillance should begin at age 25-30 and continue every 1-3 years 1.

Additional Considerations

  • Genetic counseling is recommended for all patients with suspected familial gastric cancer to identify appropriate candidates for genetic testing and determine the optimal surveillance strategy 1.
  • Artificial intelligence tools may be useful for the detection of early gastric neoplasia, but data are too preliminary to recommend routine use 1.

From the Research

Familial Stomach Cancer Surveillance

  • Familial stomach cancer is a significant concern, with approximately 10% of patients showing familial clustering, and 3% showing autosomal dominance and high penetrance 2.
  • Individuals with a family history of gastric cancer are at increased risk, and surveillance strategies are crucial for early detection and prevention.

Risk Factors and Surveillance

  • Having first-degree relatives diagnosed with gastric cancer is a strong and consistent risk factor for gastric cancer 3.
  • Current or past Helicobacter pylori infection, having two or more first-degree affected relatives, or female gender are associated with an increased risk of developing gastric cancer in individuals with a family history 3.
  • Helicobacter pylori eradication is recommended for individuals with a family history of gastric cancer, particularly those in their 20s and 30s, to prevent the progression to intestinal metaplasia and reduce the synergistic effect on gastric carcinogenesis 4, 3.
  • Endoscopic surveillance is expected to benefit individuals with a family history, with a recommended surveillance interval of 2 years instead of 3 years to detect early gastric cancer in those who have already developed precancerous gastric lesions 4.

Hereditary Diffuse Gastric Cancer (HDGC)

  • HDGC is an autosomal-dominant, inherited cancer syndrome in which affected individuals develop diffuse-type gastric cancer at a young age, with a 70% lifetime risk of developing diffuse gastric cancer for CDH1 mutation carriers 2.
  • Prophylactic total gastrectomy is recommended for CDH1 mutation carriers, as endoscopic surveillance is ineffective in identifying early HDGC 5, 2, 6.
  • Gene-directed prophylactic total gastrectomy is offered for CDH1 mutation carriers, with consideration of total gastrectomy at an age 5 years younger than the youngest family member who developed gastric cancer 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.